Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PPI Study of oral vancomycin in postprandial inflammation
NL-OMON43287Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2017
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Open-label trial of vancomycin in cardiometabolic risk (CMR) and insulin resistance (IR) (2 cohorts), sponsored by Amsterdam University Medical Center. Primary endpoint: Postprandial bacterial translocation after oral vancomycin. Started Jan 2017; status: active, not recruiting.
02
Drugs
vancomycin
03
Conditions
cardiometabolic risk (CMR)insulin resistance (IR)
Beyond the preview
Go deeper on NL-OMON43287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43287.